Merck & Co., Inc. (MRK) fair value analysis

S&P 500 · Updated 2026-09-07

Merck & Co., Inc. is a pharmaceutical company that discovers, develops, manufactures, and sells medicines, vaccines, and healthcare products for human and animal health. The company operates globally across multiple countries and regions, with significant operations in the United States and international markets.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, MRK is trading at a 10–25% premium to estimated fair value.

MRK currently ranks #95 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $150.33
Sector: Healthcare
12-month range: $82.49–$149.86

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for MRK

Our model validated 17 trailing price-to-earnings windows for MRK, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $82.49–$149.86.
The 14-day relative strength index sits at a neutral 67.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MRK
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MRK news

TickrTrends' derived news-sentiment signal for MRK is currently leaning positive, computed from recent coverage.

Top Stock Reports for Oracle, Merck & Union Pacific (zacks.com, 2026-09-08)
TickrTrends take: Merck appears in top stock reports alongside other major companies, which typically reflects analyst attention on the names. Given TickrTrends' current assessment that MRK is overvalued within the Healthcare sector, investors focused on valuation metrics should monitor whether upcoming earnings or pipeline developments narrow the gap between current market pricing and intrinsic value estimates. Any material shifts in analyst sentiment or company fundamentals would be relevant signals for re-evaluating the overvaluation designation.

What people are saying

Follow the MRK conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — Based on TickrTrends' derived indicators, MRK moved from a fairly valued DCF cross-check band assessment to an undervalued position this week, while maintaining an overall overvalued valuation verdict. This shift suggests that MRK's intrinsic value estimates have increased relative to its current market price according to the DCF analysis component of TickrTrends' methodology.
2026-09-06 — MRK's valuation indicators showed mixed movement this week. The DCF cross-check band shifted from undervalued to fairly valued, suggesting improved alignment between intrinsic value estimates, while the momentum indicator declined from A-rated to none, indicating weakening price momentum. Despite these changes, the current valuation verdict remains overvalued according to TickrTrends' derived indicators.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MRK stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MRK is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is MRK's TickrTrends verdict?

MRK's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does MRK compare to other Healthcare stocks?

MRK ranks #95 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MRK overbought or oversold?

MRK's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MRK vs BMY · MRK vs CAH · MRK vs CNC · MRK vs CRL · MRK vs CVS